Hydroxychloroquine Protects Ovaries From Chemotherapy Damage in Preclinical Study

Chemotherapy saves lives but often comes with devastating side effects, including premature ovarian failure that can rob young cancer patients of their fertility. This groundbreaking study reveals that hydroxychloroquine, a well-known anti-malarial drug, might offer protection against this reproductive damage.

Researchers used mice treated with cyclophosphamide, a common chemotherapy drug, to model premature ovarian failure. They tested whether hydroxychloroquine could prevent the ovarian damage by giving it alongside the chemotherapy treatment. The team also studied human ovarian cells in laboratory conditions to understand the underlying mechanisms.

The results were remarkable. Hydroxychloroquine significantly reduced ovarian damage, preserved egg-containing follicles, improved hormone levels, and enhanced reproductive outcomes. The drug worked by targeting cellular aging processes in granulosa cells, which support egg development. Specifically, it stabilized mitochondrial membranes, reduced harmful reactive oxygen species, and prevented mitochondrial DNA from leaking into the cell cytoplasm where it triggers inflammatory aging pathways.

For longevity and reproductive health, these findings suggest a potential strategy for preserving fertility during cancer treatment. The drug's ability to combat cellular senescence and protect mitochondrial function could have broader anti-aging applications beyond reproductive health. However, this research was conducted in mice and cell cultures, so human clinical trials are essential before any therapeutic recommendations can be made. The optimal dosing, timing, and long-term safety profile in cancer patients remain unknown.